Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Costanza De Maria"'
1
When and how to use direct oral anticoagulants in patients with advanced chronic liver disease?
Autor: Costanza De Maria, Alberto Fasoli, Andrea De Gottardi, Antonio Galante
Publikováno v: Current Opinion in Pharmacology. 60:111-116
Direct oral anticoagulants (DOACs) emerged as effective and safe alternatives to traditional anticoagulants for the prevention and treatment of venous thromboembolic disease and the prevention of stroke in non-valvular atrial fibrillation. Patients w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::182f87a69acfb9b0dfce3dfdab382b28
https://doi.org/10.1016/j.coph.2021.07.006
Zobrazit plný text záznamu
2
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease
Autor: Giorgia Bodini, Maria Giulia Demarzo, Edoardo G. Giannini, I. Baldissarro, Vincenzo Savarino, Claudia Coppo, Edoardo Savarino, Margherita Saracco, Costanza De Maria
Publikováno v: Scandinavian Journal of Gastroenterology. 54:1220-1225
Objectives: Up to 40% of inflammatory bowel disease (IBD) patients treated with anti-TNF drugs lose response within 1 year of treatment, therefore requiring drug optimization. Although high...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfe7c36536f685bf2a18f4c747380292
https://doi.org/10.1080/00365521.2019.1666914
Zobrazit plný text záznamu
3
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease
Autor: Costanza De Maria, Nicola de Bortoli, Manuele Furnari, Patrizia Zentilin, Giorgia Bodini, Marzio Frazzoni, Vincenzo Savarino, Salvatore Tolone, Elisa Marabotto, Edoardo Savarino
Publikováno v: Expert review of clinical pharmacology. 13(4)
Introduction: Gastro-esophageal reflux disease (GERD) is a highly prevalent, chronic, relapsing disorder, whose knowledge has increased in last years thanks to the advent of new sophisticated techniques, such as 24-h impedance-pH monitoring and high-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de8f60478d8e82060b57acd5242edf54
https://pubmed.ncbi.nlm.nih.gov/32253948
Zobrazit plný text záznamu
6
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease
Autor: Lorenzo Del Nero, Gaia Pellegatta, Vincenzo Savarino, Edoardo Savarino, Edoardo G. Giannini, Costanza De Maria, I. Baldissarro, Giorgia Bodini
Publikováno v: Scandinavian Journal of Gastroenterology. 51:1081-1086
Few data are available on the relevance of adalimumab (ADA) trough serum levels and anti-ADA antibodies (AAA) during long-term follow-up of patients with Crohn's Disease (CD), and their association with disease outcome. In this study, our aim was to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::603828efea80d9e52228b78579d4978a
https://doi.org/10.3109/00365521.2016.1157894
Zobrazit plný text záznamu
7
Proton pump inhibitors: use and misuse in the clinical setting
Autor: Vincenzo Savarino, Giorgia Bodini, Edoardo Savarino, Costanza De Maria, Manuele Furnari, Elisa Marabotto, Claudia Coppo, Gaia Pellegatta, Patrizia Zentilin
Publikováno v: Expert review of clinical pharmacology. 11(11)
The introduction of proton pump inhibitors (PPIs) into clinical practice has greatly improved our therapeutic approach to acid-related diseases for their efficacy and safety. Areas Covered: The following evidence-based indications for PPI use are ack
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c0b108961897da13cb7cbd3d5f65ed8
https://pubmed.ncbi.nlm.nih.gov/31305167
Zobrazit plný text záznamu
9
The appropriate use of proton-pump inhibitors
Autor: Costanza De Maria, Gaia Pellegatta, Claudia Coppo, Giorgia Bodini, Patrizia Zentilin, Manuele Furnari, Vincenzo Savarino, Elisa Marabotto, Edoardo Savarino
The introduction of proton-pump inhibitors (PPIs) into clinical practice since about thirty years has greatly improved our therapeutic approach to acid-related diseases for their well recognized efficacy and safety. Accordingly, the role of surgery h
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a4791bf2ef9cae050379217f27ed4e6
http://hdl.handle.net/11577/3294394
Zobrazit plný text záznamu
10
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index
Autor: Elisa Marabotto, Edoardo G. Giannini, Pietro Dulbecco, Edoardo Savarino, Vincenzo Savarino, Manuele Furnari, Giorgia Bodini, Costanza De Maria
Publikováno v: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 49(2)
Aims The Lemann Index (LI) was developed to assess the cumulative structural damage of the intestinal tract in patients with Crohn’s Disease (CD) independently of clinical and biochemical activity. Recently, the goal of CD focused on obtaining muco
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d394ff0d6a5de827d9583e683dc42f4
https://pubmed.ncbi.nlm.nih.gov/27864028
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje